Psychiatria pre prax 2/2020

Profile of atypical antipsychotic lurasidone

The new atypical antipsychotic lurasidone will be available for use in clinical practice. Pharmacological profile with high affinity for D2 receptors and the spectrum of action on serotonin receptors places it in the group of dopamine and serotonin antagonists. The antipsychotic has been approved in the US and Europe for several years, so there is a lot of data available on its properties. We can expect its efficacy in both the acute and maintenance phases of treatment, a high percentage of patients who do not gain weight and a proportion of patients who lose weight. The antidepressant effect has been verified and information on the pro-cognitive effect is interesting. An advantage is once daily administration. The newly available antipsychotic will important contribution to the spectrum of treatment options for schizophrenia and after practical validation of its properties, the group of patient that will have a specific benefit from the treatment may be identified.

Keywords: antipsychotics, lurasidone, schizophrenia treatment